Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on May 26, 2021 8:43pm
119 Views
Post# 33273152

RE:RE:RE:RE:RE:Volume

RE:RE:RE:RE:RE:VolumeHonestly, it would seem intensifying lack of interest in TH is impossible given the two big opportunities they have, the backdrop of a huge bull market and the hiring of a seemingly competent IR person. But every day it is staring us all in the face, so it clearly is happening. If I were the CEO and/or the board and saw all that had happened, I would be very, very alarmed.
Lee430 wrote: Good thing the board earned their full bonus by hiring a cracker jack IR director or the volume might actualy be lower...... Sorry for the sarcasim as the frustration got the better of me while listing too insane amounts of mating crazed cicadas interuputing my porch time happy hour.


scarlet1967 wrote: As per RBC direct investing 5 k shares were traded in Toronto, I don't think I have seen such low volume ever in almost a decade.
Wino115 wrote: It's really gone backward with average daily volume in the last month.  So much for replacing our tiny spigot with something bigger to make it more attractive to traders or larger investors. Pretty disturbing development from a technical perspective. No easy fix to turn that around except some outstanding data on trials or revenues. Was hoping it would start to trend higher on decent volume into June/July for some data readouts sometime in July. 

stockman75 wrote:
jeffm34 wrote: After 5 hours of trading the volume on TSX is 7000 shares traded 



Good thing our THTX is working so hard on investor relations and getting the story out or we would be at 10 or 20 shares.. LOL. 

 






<< Previous
Bullboard Posts
Next >>